Literature DB >> 33074333

The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns.

Stuart A Grossman1.   

Abstract

Entities:  

Year:  2020        PMID： 33074333      PMCID： PMC7746929          DOI： 10.1093/neuonc/noaa243

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.

Authors:  Dorothee Gramatzki; Philipp Kickingereder; Bettina Hentschel; Jörg Felsberg; Ulrich Herrlinger; Gabriele Schackert; Jörg-Christian Tonn; Manfred Westphal; Michael Sabel; Uwe Schlegel; Wolfgang Wick; Torsten Pietsch; Guido Reifenberger; Markus Loeffler; Martin Bendszus; Michael Weller
Journal:  Neurology       Date:  2017-03-15       Impact factor: 9.910

2.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

3.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

4.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

5.  A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

Authors:  Carmen Balana; Maria Angeles Vaz; Juan Manuel Sepúlveda; Carlos Mesia; Sonia Del Barco; Estela Pineda; Jose Muñoz-Langa; Anna Estival; Ramón de Las Peñas; Jose Fuster; Regina Gironés; Luis Miguel Navarro; Miguel Gil-Gil; Miriam Alonso; Ana Herrero; Sergio Peralta; Clara Olier; Pedro Perez-Segura; Maria Covela; Maria Martinez-García; Alfonso Berrocal; Oscar Gallego; Raquel Luque; Franciso Javier Perez-Martín; Anna Esteve; Nuria Munne; Marta Domenech; Salvador Villa; Carolina Sanz; Cristina Carrato
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

6.  Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Authors:  Deborah T Blumenthal; Thierry Gorlia; Mark R Gilbert; Michelle M Kim; L Burt Nabors; Warren P Mason; Monika E Hegi; Peixin Zhang; Vassilis Golfinopoulos; James R Perry; Do Hyun Nam; Sara C Erridge; Benjamin W Corn; René O Mirimanoff; Paul D Brown; Brigitta G Baumert; Minesh P Mehta; Martin J van den Bent; David A Reardon; Michael Weller; Roger Stupp
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.